Literature DB >> 15681765

Orally and nasally induced tolerance studies in ocular inflammatory disease: guidance for future interventions.

Robert Nussenblatt1.   

Abstract

The induction of both oral and nasal tolerance has been used in both experimental models of ocular disease and clinically. Initial work centered around the abrogation of experimental autoimmune uveitis using either one or two whole uveitogenic antigens. Other models of ocular disease have included a corneal transplant model, demonstrating that feeding splenocytes from the donor strain of rats enhanced corneal engraftment. Fragments of pertinent antigens have been shown to alter the expression of experimental uveitis and possibly human disease. A randomized, masked study in uveitis provided valuable information for future studies, demonstrating that single antigen feeding provided far better protection than the feeding of multiple antigens. This review will deal with animal and human studies in the treatment of ocular inflammatory disease with the goal of extracting from past experience how to construct a future study in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15681765     DOI: 10.1196/annals.1309.058

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

Review 1.  Age-related macular degeneration and the immune response: implications for therapy.

Authors:  Robert B Nussenblatt; Frederick Ferris
Journal:  Am J Ophthalmol       Date:  2007-08-15       Impact factor: 5.258

2.  CD4+LAP + and CD4 +CD25 +Foxp3 + regulatory T cells induced by nasal oxidized low-density lipoprotein suppress effector T cells response and attenuate atherosclerosis in ApoE-/- mice.

Authors:  Yucheng Zhong; Xiang Wang; Qingwei Ji; Xiaobo Mao; Hongxia Tang; Guiwen Yi; Kai Meng; Xiaofang Yang; Qiutang Zeng
Journal:  J Clin Immunol       Date:  2012-05-03       Impact factor: 8.317

3.  Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial.

Authors:  Eran Israeli; Ehud Zigmond; Gadi Lalazar; Athalia Klein; Nilla Hemed; Eran Goldin; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.